Read the latest press releases from Jubilant Biosys in the developments within the broad spectrum of CRO chemistry services, as well as our recent collaborative programs with leading global healthcare companies.
Our flexible approach helps clients understand more about our role in improving the quality of our discovery informatics, structural biology, medicinal chemistry, drug discovery services, in-vitro models and translational sciences.
Jubilant Biosys Limited seals deal with Pierre Fabre SA
Jubilant Biosys Limited to add Drug Discovery & Preclinical Development capabilities in Biologics and Antibody Drug Conjugate
Read More Jubilant Biosys Limited to add Drug Discovery & Preclinical Development capabilities in Biologics and Antibody Drug Conjugate
Jubilant Biosys announce strategic joint venture with Pierre Fabre to acquire its R&D centre in France, to enter into Biologics (mABs) and ADCs
Read More Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics.
Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry and in-vitro ADME Service offerings.
Read More Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer
Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer
Read More Jubilant Biosys and Yale University announce collaboration
New Haven, CT. & Bengaluru, India—Today, Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.
Read More Jubilant Biosys Limited Announces The Merger With Jubilant Chemsys Limited
Jubilant Biosys Limited (“Biosys”), a wholly owned subsidiary of Jubilant Life Sciences Limited, today announced completion of the merger with its sister company Jubilant Chemsys Limited, based in Noida, India. The combined entities will now operate as Jubilant Biosys Limited.
Read More Jubilant Life Sciences grants an exclusive license to Lengo Therapeutics to Discover and Develop Oncology Medicines
“Company formation is one of our core activities at Frazier, and Jubilant has been a key part of several of our early-stage companies” Daniel Estes, Ph.D., General Partner on the Frazier Life Sciences team.
Read More Jubilant Biosys Commences Major Capacity Expansions For Its Drug Discovery Services Business
Due to growing customer demand for its range of functional and integrated drug discovery services, Jubilant Biosys has started the design and construction of a brand new state-of-the-art chemistry services laboratories on the existing Jubilant Greater Noida site.
Read More Jubilant Biosys Selects CDD Vault for Discovery Research Informatics
Jubilant Biosys and Collaborative Drug Discovery (CDD) announced today, following an exhaustive evaluation, Jubilant has chosen CDD Vault as their discovery research informatics platform for the next 5 years.
Read More Jubilant Biosys is First to add ForteBio’s latest SPR System in India
Jubilant Biosys announced today that it has added advanced Pioneer FE system to its platform of drug discovery solutions available to customers. The Pioneer FE system from ForteBio represents the next generation SPR instrumentation for label-free characterization of biomolecules.
Read More